FIELD: biotechnologies.
SUBSTANCE: invention refers to peptides or peptide-like molecules of the following formula: CCLLCCLLC (I) (SEQ ID NO: 1) or CLLCCLLCC (III) (SEQ ID NO:3), where C is cationic aminoacid and L is aminoacid with lipophile group R, in which one of the aminoacids, which has lipophile group R, represents genetically uncoded aminoacid. This compound is probably in the form of pharmaceutically acceptable salt, ester or amide, and refers to their use in therapy, and namely as antitumour agents.
EFFECT: improvement of compound properties.
20 cl, 7 dwg, 12 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING OR PREVENTING CANCER DISEASE IN INDIVIDUAL, WHICH IS CHARACTERISED BY HIGH-LEVEL EXPRESSION OR ACTIVITY OF Gadd45β (AS COMPARED TO COMMON CIVILISED CELLS) IF CANCER CELL VIABILITY AND/OR GROWTH ARE/IS STATED DEPENDENT ON NF-kB, AND TRIPEPTIDE | 2010 |
|
RU2577311C2 |
| METHODS FOR INHIBITING FUCOSYLATION OF PROTEINS IN VIVO USING FUCOSE ANALOGUES | 2011 |
|
RU2625768C2 |
| PEPTIDE VACCINES FOR CANCER EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES | 2007 |
|
RU2469044C2 |
| IMPROVED METHODS FOR TREATING TUMOURS | 2007 |
|
RU2481853C2 |
| PEPTIDE, POSSESSING ANTI-TUMOR AND ANTI-METASTATIC ACTIVITY, AND FINISHED DOSAGE FORM BASED THEREON | 2018 |
|
RU2682039C1 |
| EFFECTIVE TRANSPORT INTO LEUKOCYTES | 2009 |
|
RU2558240C2 |
| METASTASIS INHIBITORS | 2014 |
|
RU2681213C2 |
| IMMUNOSTIMULATOR INDUCING TUMOR-SPECIFIC IMMUNE CELLULAR RESPONSE AND METHOD FOR ITS PREPARING | 1996 |
|
RU2206329C2 |
| POLYPEPTIDES FOR TREATING ONCOLOGICAL DISEASES | 2017 |
|
RU2728870C2 |
| USING MVA (MODIFIED VACCINIA ANKARA) FOR TREATING PROSTATE CANCER | 2008 |
|
RU2499606C2 |
